Artificial Intelligence-Enabled Screening for Tuberculosis in High-Burden Countries

In a groundbreaking collaboration, Siemens Healthineers and the Global Fund to Fight AIDS, Tuberculosis, and Malaria have joined forces to introduce AI-enabled tuberculosis (TB) screening in high-burden nations. This alliance, unveiled at the World Health Summit in Berlin, marks a significant stride towards expediting the detection of this pervasive infectious disease.

Commencing its mission in Indonesia, which harbors a staggering 9% of the world's TB infections, this initiative is poised to make a substantial impact on global health. The Global Fund, having secured an impressive $157 million in funding from 2021 to 2023, is leading the charge against TB in Indonesia.

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

Central to this innovative approach is Siemens Healthineers' partnership with, a trailblazing Indian deep-learning tech company specializing in TB X-ray software. The cloud- or on-premises software from, which has two FDA certifications for heart failure and lung X-ray platforms, has shown that it can quickly and cheaply find TB cases.

With the burgeoning potential of healthcare AI platforms, GlobalData research predicts sales will reach an astounding $18.8 billion by 2027. Siemens Healthineers and Qure.AI are poised to be frontrunners in this transformative landscape, offering free AI software licenses and comprehensive training for healthcare personnel to seamlessly integrate AI into their diagnostic routines.

Notably, the implications of this development are far-reaching. By augmenting routine chest X-ray interpretation with AI capabilities, diagnoses can be rendered swiftly and accurately. This not only expedites treatment for affected individuals but also curtails the transmission of TB. It is estimated that one untreated TB patient has the potential to infect up to 15 people annually, underscoring the urgency of early detection.

Bernd Montag, CEO of Siemens Healthineers, emphasized the significance of this endeavor, stating, "Today, we harness expertise in AI to supercharge screening programs for more precise, earlier tuberculosis diagnosis for a greater number of people." Peter Sands, the executive director of the Global Fund, echoed this sentiment and emphasized the crucial role that AI plays in overcoming the ongoing difficulties with patient identification and diagnosis in the fight against TB.

In a world where TB claims a life every two minutes, this collaboration represents a beacon of hope. By merging cutting-edge AI technology with healthcare expertise, Siemens Healthineers and the Global Fund are spearheading a transformative approach to TB detection. As the program expands beyond Indonesia, it holds the promise of fundamentally altering the trajectory of this global health crisis and setting a new standard for infectious disease screening and diagnosis worldwide.